KRAS and cancer: While the use of more than one biomarkers, for example, the use of wild-type KRAS and BRAF to select patients eligible for cetuximab41 is the emerging trend, the ability to predict chemotherapy outcomes accurately at an early time point still remains a holy grail in the management of cancer.